Prakash Raman
Patrimonio netto: 97 718 $ in data 30/09/2026
Patrimonio netto: 97 718 $ in data 30/09/2026
Dr. Prakash Raman is an Independent Director at Olema Pharmaceuticals, Inc., a Chief Executive Officer at Indupro, an Independent Director at Black Diamond Therapeutics, Inc., a Chief Executive Officer & Director at InduPro, Inc. and a President, Chief Executive Officer & Director at Ribon Therapeutics, Inc. He is on the Board of Directors at Olema Pharmaceuticals, Inc., Black Diamond Therapeutics, Inc., InduPro, Inc. and Ribon Therapeutics, Inc. Dr. Raman was previously employed as a VP & Global Head-NIBR Business Development by Novartis Institutes for Biomedical Research, Inc. and a Head-Project Management by AstraZeneca PLC.
He also served on the board at KSQ Therapeutics, Inc. and NAYA Therapeutics, Inc. He received his undergraduate degree from Indian Institute of Technology Bombay, a graduate degree from Indian Institute of Technology Bombay and a doctorate degree from the University of Wisconsin-Madison.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 18/09/2026 | 51.840 ( 0,09% ) | 97 718 $ | 30/09/2026 | |
| 18/06/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 10/04/2024 |
| OLEMA PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 28/04/2026 |
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops cacner therapies | Amministratore Delegato | 17/02/2022 |
Indupro | Amministratore Delegato | 13/06/2024 |
InduPro, Inc.
InduPro, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies | Amministratore Delegato | 01/04/2024 |
| Società | Posizione | Fine |
|---|---|---|
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | 01/10/2019 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/11/2012 |
KSQ Therapeutics, Inc.
KSQ Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops therapeutics for cancer | Amministratore Delegato | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 9 |
|---|---|
AstraZeneca PLC
AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Indian Institute of Technology Bombay
Indian Institute of Technology Bombay Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops cacner therapies | Health Technology |
KSQ Therapeutics, Inc.
KSQ Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops therapeutics for cancer | Health Technology |
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for the treatment & prevention of estrogen receptor positive breast cancer | Health Technology |
Indupro | |
InduPro, Inc.
InduPro, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale